FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy QURE?
Source: CNBC
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.580
Low
33.00
Averages
49.88
High
70.00
Current: 17.580
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
uniQure Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors that uniQure N.V. is facing a class action lawsuit aimed at recovering losses for investors affected between September 24, 2025, and October 31, 2025, indicating significant legal risks that could impact the company's stock performance.
- Allegations Overview: The lawsuit alleges that uniQure's pivotal study design was not fully approved by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies, which may undermine investor confidence in the company's future prospects.
- Investor Rights Protection: Affected investors have until April 13, 2026, to request to be appointed as lead plaintiff, allowing them to participate in the lawsuit and potentially receive compensation without any out-of-pocket costs, providing a legal recourse for investors.
- Law Firm Credentials: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, highlighting its expertise and credibility in handling such cases.
See More
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study by the FDA, which has led to investor losses when the true details were revealed, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and expertise, urging investors to select qualified legal counsel.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they have appropriate legal representation in the class action.
See More
uniQure Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between September 24 and October 31, 2025, with a deadline to contact the firm by April 13, 2026.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, which resulted in significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- BLA Timeline Delays: uniQure is accused of misleading the market regarding its ability to submit its Biologics License Application (BLA) on time and failing to supplement the data submitted to the FDA, further exacerbating the risk of investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests.
See More
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
- Deadline for Filing: Investors in uniQure N.V. must submit lead plaintiff applications by April 13, 2026, to participate in a securities class action lawsuit concerning shares purchased between September 24 and October 31, 2025, highlighting significant investor concern over corporate transparency.
- Stock Price Plunge: Following the FDA's delay in approving AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29 on November 3, 2025, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Accountability Claims: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, indicating serious deficiencies in the company's information disclosure practices that could erode investor trust.
- Legal Consultation Availability: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact KSF law firm, demonstrating the company's commitment to investor rights and the necessity of legal support.
See More
uniQure N.V. Shareholder Files Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025, and October 31, 2025, alleging misrepresentations regarding the drug AMT-130, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiff must file papers by April 13, 2026, with the lead plaintiff representing other class members in the litigation, although one can still share in any recovery without being the lead.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, highlighting its influence in the legal field.
- Transparent Fee Structure: All representation by the law firm is on a contingency fee basis, meaning shareholders incur no fees or expenses, ensuring fair treatment for all investors involved in the legal proceedings.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
uniQure Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors that uniQure N.V. is facing a class action lawsuit aimed at recovering losses for investors affected between September 24, 2025, and October 31, 2025, indicating significant legal risks that could impact the company's stock performance.
- Allegations Overview: The lawsuit alleges that uniQure's pivotal study design was not fully approved by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies, which may undermine investor confidence in the company's future prospects.
- Investor Rights Protection: Affected investors have until April 13, 2026, to request to be appointed as lead plaintiff, allowing them to participate in the lawsuit and potentially receive compensation without any out-of-pocket costs, providing a legal recourse for investors.
- Law Firm Credentials: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, highlighting its expertise and credibility in handling such cases.
See More
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study by the FDA, which has led to investor losses when the true details were revealed, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and expertise, urging investors to select qualified legal counsel.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they have appropriate legal representation in the class action.
See More
uniQure Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between September 24 and October 31, 2025, with a deadline to contact the firm by April 13, 2026.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, which resulted in significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- BLA Timeline Delays: uniQure is accused of misleading the market regarding its ability to submit its Biologics License Application (BLA) on time and failing to supplement the data submitted to the FDA, further exacerbating the risk of investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests.
See More
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
- Deadline for Filing: Investors in uniQure N.V. must submit lead plaintiff applications by April 13, 2026, to participate in a securities class action lawsuit concerning shares purchased between September 24 and October 31, 2025, highlighting significant investor concern over corporate transparency.
- Stock Price Plunge: Following the FDA's delay in approving AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29 on November 3, 2025, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Accountability Claims: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, indicating serious deficiencies in the company's information disclosure practices that could erode investor trust.
- Legal Consultation Availability: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact KSF law firm, demonstrating the company's commitment to investor rights and the necessity of legal support.
See More
uniQure N.V. Shareholder Files Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025, and October 31, 2025, alleging misrepresentations regarding the drug AMT-130, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiff must file papers by April 13, 2026, with the lead plaintiff representing other class members in the litigation, although one can still share in any recovery without being the lead.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, highlighting its influence in the legal field.
- Transparent Fee Structure: All representation by the law firm is on a contingency fee basis, meaning shareholders incur no fees or expenses, ensuring fair treatment for all investors involved in the legal proceedings.
See More
